Skip to main content
Erschienen in: Reactions Weekly 1/2018

01.06.2018 | Case report

Eslicarbazepine acetate

Amnesia and agitation: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Salpekar J, et al. Analysis of cognitive adverse events in two phase iii conversion-to-eslicarbazepine acetate (ESL) monotherapy trials. Neurology 90 (Suppl. 15): abstr. P5.277, 10 Apr 2018 [abstract] - USA Salpekar J, et al. Analysis of cognitive adverse events in two phase iii conversion-to-eslicarbazepine acetate (ESL) monotherapy trials. Neurology 90 (Suppl. 15): abstr. P5.277, 10 Apr 2018 [abstract] - USA
Metadaten
Titel
Eslicarbazepine acetate
Amnesia and agitation: 3 case reports
Publikationsdatum
01.06.2018
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-018-47524-9

Weitere Artikel der Ausgabe 1/2018

Reactions Weekly 1/2018 Zur Ausgabe

Case report

BCG-vaccine

Case report

Gabapentin

Case report

Fluoxetine

Case report

Rituximab

Case report

Quinidine